Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort.

Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort.

INTRODUCTION:Studies on metabolomics and CKD have primarily addressed CKD incidence defined as a decline on eGFR or appearance of albuminuria in the general population, with very few evaluating hard outcomes. In the present study, we investigated the association between metabolites and mortality and...

Full description

Bibliographic Details
Main Authors: Silvia M Titan, Gabriela Venturini, Kallyandra Padilha, Alessandra C Goulart, Paulo A Lotufo, Isabela J Bensenor, Jose E Krieger, Ravi I Thadhani, Eugene P Rhee, Alexandre C Pereira
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0213764

Internet

https://doi.org/10.1371/journal.pone.0213764

Similar Items